Sentynl Signs Deal With Fortress’ Cyprium For ‘De-Risked’ Rare Disease Drug
Executive Summary
Deal Snapshot: Sentynl will pay $20m in upfront and regulatory milestone payments through FDA approval, while Cyprium will retain 100% ownership of the priority review voucher.
You may also be interested in...
Zydus Claims Top Spot In India Biosimilars With Kadcyla, Sees 40-50% Growth
Zydus Cadila sees 40-50% growth continuing in its biosimilars business, with plans for launches in Latin America. Its Kadcyla biosimilar is faring well and after helping the company gain the top spot in India, could also move to clinical trials in the US.
Deal Watch: ICON, PRA Health Form Massive CRO In $12bn Merger
Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia
Mustang Bio Joins RMAT List; Eiger Brings Home Its 4th BTD
Gene therapy and lambda interferon products are highlighted in the new Review Pathways section of the US FDA Performance Tracker, which keeps track of breakthrough therapy (BTD), regenerative medicine advanced therapy (RMAT), qualified infectious disease product (QIDP) designations and biosimilar submissions.